Moderna's mRNA Pipeline Could Reshape the Company Beyond COVID-19 Vaccines

Moderna Eyes Multiple FDA Milestones as Stock Surges Over 100% in 2026

Moderna (NASDAQ: MRNA) has spent the past several years clawing its way back from a steep post-pandemic decline, and 2026 is shaping up to be a pivotal year for the Cambridge-based biotech. With shares already more than doubling year-to-date, investor attention has shifted toward a series of upcoming regulatory decisions and clinical data readouts that could define the company's next chapter.

Flu Vaccine Decision Looms Large

The most immediate catalyst on Moderna's calendar centers on mFlusiva, its mRNA-based seasonal influenza vaccine. The FDA has set an August 5 target action date following the submission of briefing documents to its advisory committee, which characterized the vaccine's efficacy data in largely positive terms.

If the agency grants approval, mFlusiva could reach pharmacy shelves in time for the 2026–2027 flu season. That said, the path isn't entirely clear. An FDA advisory committee recently raised questions about the study's methodology, though notably stopped short of identifying any major deficiencies in efficacy data. The outcome remains uncertain, and market observers are watching closely.

Also generating optimism is Moderna's combination flu-and-COVID-19 vaccine, mCOMBRIAX. The European Commission approved the product last month for adults aged 50 and older, and phase 3 trial data demonstrated it outperformed existing stand-alone vaccines for both viruses. From a public health standpoint, combining the two vaccines into a single shot addresses a well-documented challenge in immunization: patients who might skip a COVID-19 booster separately are more likely to receive it when bundled with an annual flu visit.

Cancer Vaccine Partnership With Merck Draws Investor Attention

Beyond respiratory vaccines, perhaps the most closely watched program in Moderna's pipeline is intismeran autogene (mRNA-4157), a personalized cancer vaccine being co-developed with Merck. The therapy works by encoding mRNA instructions tailored to the specific mutations on an individual patient's tumor cells, directing the immune system to attack them directly.

In January, Moderna presented five-year phase 2 results in high-risk melanoma patients, showing durable efficacy when intismeran was used alongside Merck's Keytruda. Analysts note that the data held up impressively over that time horizon. Pivotal phase 3 readouts are expected later in 2026, and a positive outcome could mark Moderna's entry into oncology — a development that would carry significant implications for how the market values the company's long-term prospects.

Expansion Plans and Financial Realities

Moderna is restructuring internally to prepare for what it describes as up to three new product launches between 2027 and 2028. These span infectious disease (including a norovirus vaccine candidate), oncology, and rare diseases, with a therapy for propionic acidemia among the rare disease targets. The company recently brought in a new chief commercial officer to lead global launch execution.

First-quarter 2026 financials present a mixed picture. Revenue came in at $389 million, representing a 260% year-over-year increase. However, the company posted an earnings per share loss of $3.40, compared to a loss of $2.52 in Q1 2025. A significant portion of that gap stems from a one-time $878 million litigation charge. Stripping out that item, adjusted EPS reflected a loss of $1.18 versus $0.88 in the prior-year period — an improvement in the underlying trend, though still firmly in the red.

On the balance sheet, Moderna holds $7.5 billion in cash with minimal debt, providing what management characterizes as a multi-year runway toward its stated goal of companywide breakeven by 2028.

What Investors Are Watching

Because Moderna currently trades at a premium price-to-sales ratio relative to its existing revenue base, the stock's current valuation reflects forward-looking expectations rather than present earnings power. Market participants are essentially pricing in the probability that upcoming FDA decisions, phase 3 data, and commercial launches will validate the broader mRNA platform.

Key dates and developments to monitor include the August 5 FDA decision on mFlusiva, phase 3 intismeran data expected later this year, and any further regulatory updates on the combination COVID-19 and flu vaccine in the United States. Each of these milestones carries the potential to meaningfully move the stock in either direction.